Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

BACKROUND: Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor BKM120 in advanced or recurrent endometrial carcinoma. METHODS: This phase II,...

Descripción completa

Detalles Bibliográficos
Autores principales: Heudel, P-E, Fabbro, M, Roemer-Becuwe, C, Kaminsky, M C, Arnaud, A, Joly, F, Roche-Forestier, S, Meunier, J, Foa, C, You, B, Priou, F, Tazi, Y, Floquet, A, Selle, F, Berton-Rigaud, D, Lesoin, A, Kalbacher, E, Lortholary, A, Favier, L, Treilleux, I, Ray-Coquard, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294485/
https://www.ncbi.nlm.nih.gov/pubmed/28072765
http://dx.doi.org/10.1038/bjc.2016.430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294485/
https://www.ncbi.nlm.nih.gov/pubmed/28072765
http://dx.doi.org/10.1038/bjc.2016.430

Ejemplares similares